telisotuzumab vedotin

FDA grants breakthrough designation to AbbVie’s Teliso-V for NSCLC treatment
Pharmaceutical Business Review
Wed, 01/5/22 - 10:33 am
FDA
AbbVie
Teliso-V
telisotuzumab vedotin
non-small cell lung cancer